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Background: Calciﬁed amorphous tumor (CAT) of the heart is a rare non-neoplastic intracavitary cardiac mass.
Several case reports have been published but large series are lacking.
Objective: To determine clinical features, current management and outcomes of this rare disease.
Design: A systematic review of all articles reporting cases of CAT in order to perform a pooled analysis of its
clinical features, management and outcomes.
Data sources: An electronic search of all English articles using PUBMED was performed. Further studies were
identiﬁed by cross-referencing from relevant papers.
Inclusion criteria: We restricted inclusion to articles reporting cases of CAT in the English language literature
published up to July 2014.
Data extraction: One author performed data extraction using predeﬁned data ﬁelds.
Results: A total of 27 articles, reporting 42 cases of CAT were found and included in this review.
Conclusion: In this review, the most frequent presenting symptoms were dyspnea and embolic events. Mitral
valve and annulus were the most frequent location of CAT. Surgery was most of the time required to conﬁrm
diagnosis, and was relatively safe. Overall outcome after surgical resection was good.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ /).4.01. Introduction
Calciﬁed amorphous tumor (CAT) of the heart is a rare non-
neoplastic intracavitary cardiacmass,withmicroscopic features of calci-
ﬁcation and amorphous ﬁbrinous material. Since its ﬁrst description in
1997 as a speciﬁc entity by Reynolds and colleagues [1], several case
reports have been published. Still, large series are lacking and, to date,
we have no clear overview of the scope of the disease. In this article,
we aim to perform a systematic review of the literature and to build a
registry of all published cases of CAT in order to determine its clinical
features, current management and prognosis.2. Methods
We performed a systematic search using PubMed, according to the
preferred reporting items for systematic reviews and meta-analysis
(PRISMA) guidelines, for articles reporting cases of CAT in the English
language literature. Additional articles were identiﬁed by a manual
search of references of relevant papers. Authors of articles were
contacted, if needed, to obtain additional data that was of interest to25353362.
tinne),
oss@ulb.ac.be
land Ltd. This is an open access article uour review. We included all articles published since the ﬁrst report
(May 1st, 1997) up to July 31st, 2014. The titles and abstract of the
identiﬁed articles were screened to determine if they met inclusion
criteria. Full text articles were then retrieved and reviewed. Reference
lists of the retrieved articles were searched for relevant literature.
Predetermined variables were ﬁrst author, year of publication, title,
journal, patient clinical informations (age, gender…), tumor size and
location, presenting symptoms, associated conditions, treatment,
follow-up and outcome.3. Results
A total of 27 articles reporting 42 cases of CAT were found. Table A
lists the clinical characteristics of the patients. Table B reports thepooled
clinical data. The mean age at presentation was 54 years (range 16–85),
with a female predominance (64%). CAT was detected in all cardiac
chambers, but predominated on the mitral valve or annulus (36%), in
the right atrium (21%) or the right ventricle (17%). Mean tumor size
was 29 × 17 mm, ranging from 1.7 mm punctate lesion to very large
masses (20 × 90mm) or even diffuse left ventricular (LV) inﬁltration.
The most frequent presenting symptom was dyspnea (45%) follow-
ed by syncope (21%). Pulmonary or systemic embolizationwas reported
in 31% of the cases. CAT was discovered incidentally in 17% of the
patients.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ /).4.0
Table A
Clinical characteristics of published cases of calciﬁed amorphous tumor.
Report Case
no
Sex Age Tumor site Presentation Follow-up Comorbidities/underlying
disease
Size (mm) Treatment
Reynolds et al.
(1997) [1]
1 M 16 LA Exercise
intolerance,
near-syncope
Residual calciﬁcations in LA Mediastinal RT and
chemo for neuroblastoma
at age 3 months
45 × 23 ×
3
Surgical excision
2 M 30 LV Near-syncope, chest
pain, palpitations
Small residual calciﬁed nodule
in LV, 3 years 6 months
None 30 × 12 ×
10
Surgical excision
3 F 33 RV Shortness of breath Lost to follow-up Recurrent PE 20 × 23 Surgical excision
4 F 34 RV Vertigo, orthopnea Lost to follow-up Systemic lupus-like
illness
35 × 25 ×
15
Surgical excision
5 F 48 MV CVA NED 4 months MR and TR, cleft mitral
valve leaﬂet
30 × 2 Surgical excision
6 F 60 LV, MV CVA, retinal emboli Alive, left jugular foramen
tumor
MR and AR with enlarged
LA
15 × 15 ×
15
Surgical excision
7 M 65 RV, TV Shortness of breath Died of non cardiac cause 30
days after diagnosis
CAD, recurrent PE 33 × 27 ×
12
No surgery
8 F 67 RA Syncope NED 18 years CAD, CHF 65 × 50 ×
50
Surgical excision
9 M 67 LV Syncope NED 1 year 4 months CAD, ESRD, tumoral
calcinosis
15 × 3 × 3 Surgical excision
10 F 73 RA, SVC Dizziness, dyspnea
on exertion
NED 1 year 5 months Diverticulitis, partial
resection, total parenteral
nutrition
20 × 90 Surgical excision
11 F 75 LV “Funny sensation”
in chest
NED 6 years 11 months Diabetes mellitus 20 × 20 ×
20
Surgical excision
Chaowalit et al.
(2005) [15]
12 F 20 RV PE, dyspnea N/A Chest trauma 3 years
earlier
40 × 22 ×
18
Surgical excision
Lewin et al.
(2006) [12]
13 F 60 RV Syncope Died 1 day after surgery No prior cardiac history. 40 × 30 ×
25
Surgical excision
Fealey et al.
(2007) [14]
14 F 20 RV PE, cough,
shortness of breath,
fatigue
Residual calciﬁed RV nodule,
recurrent PE 2 years after
surgical resection, second
resection
None 40 × 35 ×
25
Surgical excision
Khulbey et al.
(2008) [16]
15 M 26 RA Prolonged fever and
constitutional
symptoms
NED 1 year Atrial septal closure 30 × 20 ×
20
Surgical excision
Inamdar et al.
(2008) [17]
16 F 85 MA Chronic fatigue N/A MAC, ESRD, HTN, DM 23 × 9 Surgical excision
Ho et al.
(2008) [3]
17 M 44 LV and mitral
chordal apparatus
diffuse
inﬁltration
Shortness of breath
on exertion
N/A Severe LV systolic
dysfunction
Diffuse
inﬁltration
Referred for heart
transplantation
Gutierrez et al.
(2008) [18]
18 M 35 RA Septic shock NED 2 months ESRD (Alport syndrome),
HTN
20 × 15 ×
14
Surgical excision
Flynn et al.
(2009) [19]
19 M Young RV Syncope, PE, severe
tricuspid
regurgitation
N/A N/A 14 × 12 ×
5
Surgical excision
and pulmonary
TEA
Habib et al.
(2010) [5]
20 F 58 MA, MV, diffuse
LV inﬁltration
Ventricular
tachycardia
Medical treatment, persistent
VT
Ventricular tachycardia,
SCD, mild mitral
regurgitation
Diffuse
inﬁltration
Medical treatment
Gupta et al.
(2010) [20]
21 F 40 RA Shortness of breath
on exertion, cough,
fatigue
NED 8 months None 30 × 20 ×
15
Surgical excision
Vaideeswar
et al. (2010)
[13]
22 M 56 RA Progressive
shortness of breath,
PE, blurring of
vision
NED 2 years N/A N/A Surgical excision
and pulmonary
TEA
23 M 35 RA Exertional dyspnea,
dizziness on
walking, PE
Died 7 days after surgery N/A 32 × 23 ×
13
Surgical excision
and pulmonary
TEA
Kubota et al.
(2010) [8]
24 F 64 LV, MA Incidental NED 3 years ESRD, DM 3 × 27 Surgical excision
25 M 44 LV, PM Incidental NED 3 years ESRD 6 × 28 Surgical excision
Greaney et al.
(2011) [21]
26 F 69 LV, MV Left-sided heart
failure, stroke
NED 3 months Severe COPD 20 Surgical excision
Ananthakrishna
et al. (2011)
[22]
27 F 45 LV Breathlessness NED 4 months Rheumatic heart disease 40 × 35 ×
20
Surgical excision,
mitral and aortic
valve replacement
Vlasseros et al.
(2011) [2]
28 F 65 LV, MV Visual loss (central
retinal artery
occlusion)
NED 8 months DM, HTN 26 × 17 ×
5
Surgical excision
and MVR
Lin et al.
(2011) [23]
29 F 74 LA Incidental NED 6 months None 14 × 27 Surgical excision
De Sousa et al.
(2011) [24]
30 M 17 TV Cardiomegaly NED 3 months Ebstein anomaly 15 × 15 ×
13
Surgical excision
and TV
valvuloplasty
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Table A (continued)
Report Case
no
Sex Age Tumor site Presentation Follow-up Comorbidities/underlying
disease
Size (mm) Treatment
Fujiwara et al.
(2012) [7]
31 M 58 MA Incidental N/A ESRD, MAC N/A Surgical excision
32 M 65 MA Incidental N/A ESRD, MAC 7 × 2 Surgical excision
Nishigawa
et al. (2012)
[25]
33 F 78 LA Incidental N/A MAC 1.7 Surgical excision
Nazli et al.
(2013) [4]
34 F 54 LV Central retinal
artery occlusion
NED 1 year Hypothyroidism 38 × 25 Surgical excision
Yamamoto
et al. (2013)
[26]
35 F 82 MA Progressive heart
failure
N/A N/A 37 × 4 Surgical excision
Kawata et al.
(2013) [9]
36 M 59 MA Incidental N/A DM, ESRD, MAC 28 × 6 Surgical excision
Rehman et al.
(2014) [27]
37 F 62 RV Severe exertional
dyspnea, chronic
pulmonary
embolism
N/A Atrial septal defect 30 × 20 Surgical excision
Mohamedali
et al. (2014)
[10]
38 F 69 MA Dyspnea, epigastric
pain
N/A ESRD, MAC 7 × 3 × 3 Surgical excision
Choi et al.
(2014) [28]
39 F 57 RA Dyspnea, fever,
cough
NED 1 year N/A 19 × 13 ×
8
Surgical excision
Hussain et al.
(2014) [29]
40 F 80 LV Near-syncope N/A HTN, dyslipidemia, CAD,
lung adenocarcinoma
50 Surgical excision
41 F 69 MV Palpitations N/A HTN, DM, dyslipidemia 10 × 10 Surgical excision
and MV
valvuloplasty
42 F 60 RA Dyspnea N/A Breast cancer 10 years
earlier
16 × 23 Surgical excision
AR: aortic regurgitation, CAD: coronary artery disease, COPD: chronic obstructive pulmonary disease, CVA: cerebrovascular accident, DM: diabetesmellitus, ESRD: end-stage renal disease,
F: female, HTN: hypertension, LA: left atrium, LV: left ventricle, M:male, MA: mitral annulus, MAC:mitral annular calciﬁcation, MR: mitral regurgitation, MV: mitral valve, N/A: not avail-
able, NED: no evidence of disease, PE: pulmonary embolism, PM: papillary muscle, RA: right atrium, RT: radiotherapy, RV: right ventricle, SCD: sudden cardiac death, TEA:
thromboendarterectomy, TR: tricuspid regurgitation, TV: tricuspid valve, VT: ventricular tachycardia.
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concomitantwithMAC (14%), end-stage renal disease (ESRD) (21%), di-
abetes (14%), and coronary artery disease (12%).
Surgery was performed in most of the reported cases (93%), with a
vast majority of favorable outcomes. Nonetheless, two patients died
postoperatively (5%). Medical treatment was favored in 2 cases present-
ing diffuse calcium inﬁltration of the LV. Recurrence occurred in 1 case
and residual calciﬁcations were observed in 14% on follow-up imaging
studies. Themean follow-upwithout evidence of diseasewas 12months.Fig. 1. 2D echocardiography of CAT (personal unpublished data). Echocardiographic four
chamber view (Panel A) showing a mobile mass of 7 × 9 mm, attached on the ventricular
side of the mitral annulus, close to the posterior commissure. Zoom view (Panel B) allows
characterizing the relationship of the mass (small arrows) with the mitral leaﬂets (large
arrows). LV, left ventricle; LA, left atrium.4. Discussion
This review, encompassing all published cases of CAT allows giving a
scope of this rare disease. However, there might have been some bias.
Indeed, the condition is inherently underreported, since suspected but
unoperated and thus unconﬁrmed cases were probably, were probably
most of the time not reported.
Pathophysiologic hypotheses involving an organized thrombus ori-
gin favored by hypercoagulability [1] and/or phosphocalcic metabolism
abnormalities [2] have been raised, but the pathogenesis of CAT remains
poorly understood. Our review does not support the hypothesis of
hypercoagulability.
Although endomyocardial biopsy was used for diagnosis in one case
of diffuse LV inﬁltration [3], ruling out other cardiac masses or
neoplasms requires surgery for histological conﬁrmation in most of
the cases, as clinical presentation of patients with cardiac masses
tends to be similar. Current imaging cardiac techniques do not speciﬁ-
cally differentiate cardiac CAT from other masses, but some features
may contribute to establish the diagnosis [4]. On echocardiography,
CAT usually appears as a calciﬁed endocavitarian mass that may be
located in any cardiac chamber, on any valves or on valvular annuli
(Fig. 1). Size can vary from small punctate lesions to very large masses.Diffuse LV myocardial inﬁltrations have been reported [3,5] but these
forms probably constitute a distinct type of disease.
Because of the calciﬁcations, CAT can bemistaken for osteosarcoma,
calciﬁed myxoma or vegetations on imaging studies but the histopath-
ologic appearance of the former is straightforward and entirely benign
as it is composed of nodular calcium deposits surrounded by an
amorphous hyalinized material [6] (Fig. 2). Clinical characteristics of
the patient are also helpful, as patients frequently present concomitant
conditions such as pre-existing valve disease (MAC for instance), end-
stage renal disease (ESRD), or other cardiovascular risk factors. MAC-
Fig. 2. CATmicroscopic image (personal unpublished data). Microscopic ﬁndings showing
heterogeneous calcium deposits with surrounding amorphous eosinophilic and ﬁbrinous
material (hematoxilin and eosin, original ×100).
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associated with ESRD [7–10]. Kubota and colleagues proposed the
descriptive termof “swinging calciﬁed amorphous tumor” formobile le-
sions arising from aMAC [8]. This subgroup of CAT seems to carry a high
embolic risk, and rapid growth characteristics. Because of its mobile
characteristics, one might postulate that CAT may causally contribute
to the occurrence of stroke. However, the presence of MAC in itself is
associated with an increased risk of stroke, independently of traditional
risk factors [11]. In the current registry, CATwas associatedwith ESRD in
21% and with MAC in 14% of the patients.
The discovery of CATmay be incidental, but most of the time symp-
toms are related to embolization or obstruction, depending on its sizeTable B
Demographic and clinical data of the population. (n = 42).
Variables Values
Male gender 15 (36)
Age, years 54 ± 18
CAT localization
Mitral valve or annulus 15 (36)
Right atrium 9 (21)
Right ventricle 7 (17)
Left ventricle 6 (14)
Left atrium 3 (7)
Tricuspid valve or annulus 2 (5)
Tumor size, mm 29 ± 16 × 17 ± 11
Clinical presentation (multiple symptoms possible)
Dyspnea 19 (45)
Syncope 9 (21)
Pulmonary embolism 8 (19)
Incidental 7 (17)
Systemic embolism 5 (12)
Chest pain 2 (5)
Other 9 (21)
Follow-up
No evidence of disease, months 12 [2-216]
Residual disease 3 (14)
Recurrence 1 (5)
No data available (lost to follow-up or unavailable data) 21 (50)
Outcome
Death (CAT or surgery related) 2 (5)
Associated conditions
Valve disease 13 (31)
End stage renal disease 9 (21)
Mitral annulus calciﬁcation 6 (14)
Diabetes mellitus 6 (14)
Coronary artery disease 5 (12)
Hypertension 4 (10)
Congestive heart failure 2 (5)
Treatment
Surgical excision 39 (93)
Other 3 (7)
Values are given as mean ± SD, no. (%), or median [range].and location. The most common presenting symptoms in this registry
were dyspnea, embolic event and syncope. An embolic event is a
frequent presenting condition and mobile lesions deﬁnitely indicate a
higher embolic risk [8]. However, traditional cardiovascular risk factors
are highly prevalent, which may contribute to the high prevalence of
cerebrovascular events at presentation. Less frequently, atypical chest
pain or ventricular arrhythmia may occur but the etiological role of
the CAT is unclear [5]. The growth rate of CAT is largely unknown, but
may be relatively fast, especially in MAC-related CAT. Indeed, tumors
growing very rapidly in a time span of 6 weeks to 1 year have been
reported [8,9].
Surgical resection remains the diagnostic and therapeutic standard for
pedunculated lesions, although it carries some procedural risk: 2 patients
(5%) died during the perioperative period [12,13]. Recurrence after
surgery seems infrequent as only 1 patient presented recurrent disease
2 years after surgical resection [14].
5. Conclusions
Our systematic review, encompassing all published cases of CAT
provides more insights into the clinical characteristics of this poorly
known disease. Patients with CAT can present a large variety of symp-
toms,most of the time related to embolization or obstructiondepending
on the size and the location of the mass, but may also be discovered
incidentally. CAT can arise from any cardiac chamber or valve, but in
this review mitral valve and annulus appear to be its most frequent
location and its size can vary from small punctate lesions to large
pedunculated masses. Surgery is most of the time required to conﬁrm
diagnosis, and appears relatively safe.MAC-related CATs seem to consti-
tute a subtype of this benign tumor, exhibiting speciﬁc characteristics
including a rapid growth and a high embolic risk.
However, the natural history of the disease, its embolic potential as
well as its best management strategy remain largely unknown. There-
fore, there is a need for collecting the clinical data and building up a
registry of all the patients presenting with echocardiographic features
suggestive of CAT, in order better characterize the natural history of
the disease, its outcome and the best therapeutic approach.
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